Foghorn Therapeutics Inc.
Datakwaliteit: 100%
FHTX
Nasdaq
Manufacturing
Chemicals
€ 4,59
▼
€ 0,20
(-4,18%)
Marktkapitalisatie: 284,70 M
Prijs
€ 4,85
Marktkapitalisatie
284,70 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue grew 120,02% annually over 5 years — strong growth
Negative free cash flow of -86,15 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 83,27%
Capital efficient — spends only 0,16% of revenue on capex
Groei
Revenue Growth (5Y)
120,02%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)36,75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-50,87%
Net Margin-240,33%
Op. Margin-279,49%
Veiligheid
Debt / Equity
N/A
Current Ratio2,16
Interest CoverageN/A
Waardering
PE (TTM)
-3,83
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1366 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,8 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | -240,3 | -41,5 |
| Rev Growth 5Y % | 120,0 | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
9 analisten
Buy
Huidig
€ 4,59
Koersdoel
€ 11,44
€ 9,00
€ 12,00
€ 14,00
Vooruitzicht
Forward K/W
-5,04
Forward WPA
-€ 0,91
Omzet Sch.
44,22 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
-€ 0,91
-€ 1,19 – -€ 0,70
|
44,22 M | 7 |
| FY2026 |
-€ 1,13
-€ 1,54 – -€ 0,79
|
33,00 M | 5 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
-€ 0,33
-€ 0,36 – -€ 0,28
|
8,15 M | 3 |
| 2026 Q1 |
-€ 0,32
-€ 0,38 – -€ 0,27
|
7,83 M | 3 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | -€ 0,26 | -€ 0,37 | -42,4% |
| Q32025 | -€ 0,30 | -€ 0,25 | +16,7% |
| Q22025 | -€ 0,32 | -€ 0,28 | +12,0% |
| Q12025 | -€ 0,29 | -€ 0,30 | -3,5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 36,75% | Revenue Growth (3Y) | -4,87% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 120,02% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 30,91 M | Net Income (TTM) | -74,28 M |
| ROE | N/A | ROA | -34,45% |
| Gross Margin | N/A | Operating Margin | -279,49% |
| Net Margin | -240,33% | Free Cash Flow (TTM) | -86,15 M |
| ROIC | -50,87% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,16 |
| Interest Coverage | N/A | Asset Turnover | 0,14 |
| Working Capital | 99,03 M | Tangible Book Value | -89,66 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -3,83 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 9,21 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -30,26% | ||
| Market Cap | 284,70 M | Enterprise Value | 195,36 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,18 | Revenue / Share | 0,53 |
| FCF / Share | -1,47 | OCF / Share | -1,47 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,16% | FCF Conversion | 115,97% |
| SBC-Adj. FCF | -97,33 M | Growth Momentum | -83,27 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 30,91 M | 22,60 M | 34,16 M | 19,23 M | 1,32 M |
| Net Income | -74,28 M | -86,62 M | -98,43 M | -108,88 M | -101,32 M |
| EPS (Diluted) | -1,18 | -1,58 | -2,34 | -2,62 | -2,73 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -86,39 M | -102,68 M | -107,91 M | -117,14 M | -100,73 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 85,47 M | 94,53 M | 109,69 M | 105,62 M | 80,33 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 3,33 M | 3,12 M | 3,45 M | 3,32 M | 3,23 M |
| Interest Expense | — | — | — | — | 1,91 M |
| Income Tax | 0,0 | 0,0 | 4,23 M | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 198,10 M | 283,98 M | 285,92 M | 404,88 M | 519,77 M |
| Total Liabilities | 306,60 M | 329,51 M | 363,11 M | 404,77 M | 422,90 M |
| Shareholders' Equity | -108,50 M | -45,53 M | -77,19 M | 112.000,0 | 96,87 M |
| Total Debt | — | — | — | — | 0,0 |
| Cash & Equivalents | 80,88 M | 55,45 M | 80,34 M | 52,21 M | 101,14 M |
| Current Assets | 163,24 M | 249,60 M | 240,18 M | 351,40 M | 459,56 M |
| Current Liabilities | 59,74 M | 66,99 M | 58,44 M | 55,21 M | 48,69 M |
{"event":"ticker_viewed","properties":{"ticker":"FHTX","listing_kind":"stock","pathname":"/stocks/fhtx","exchange":"Nasdaq","country":"US"}}